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Inflammation is critical for the development of many complex
diseases and disorders including autoimmune diseases, metabolic
syndrome, neurodegenerative diseases, cancers, and cardio-
vascular diseases. Inflammation comes in two types: chronic
inflammation, which can be defined as a dysregulated form of
inflammation, and acute inflammation, which can defined as a
regulated form. Because of its special role in the aforementioned
diseases, establishing methods to control chronic inflammation
is important for developing cures and treatments against var-
ious diseases and disorders. One challenge to achieve this has
been the ability to distinguish chronic and acute inflammation
based onmolecular biology diagnostics. Thus, this Research Topic
is focused on articles that can shed new light on the molec-
ular mechanisms responsible for the development of chronic
inflammation and its related conditions.
This volume brings together 13 articles that are intended to
provide a summary of some of the current thinking regarding the
“molecular mechanism of chronic inflammation development.”
The 13 articles are briefly described below.
The first (Chilton et al., 2012) and second articles (Shichita
et al., 2012) present the roles of TLR-mediated signals in chronic
inflammation. The authors focus a TLR4 ligand, lipid A, pro-
duced by Gram-negative bacteria and its variants to investigate
how these compounds induce acute and chronic inflammation
(Chilton et al., 2012) and post-ischemic inflammation in the
brain induced by endogenous TLR ligands, high mobility group
box 1 (HMGB1), and peroxiredoxin family proteins (Shichita
et al., 2012). Both these exogenous and endogenous TLR lig-
ands should be triggering factors for both acute as well as chronic
inflammation.
The next three articles focus on T cells in the process of
chronic inflammation. Huseby et al. (2012) review pathogenic
CD8+ T cells in multiple sclerosis (MS), while many researchers
including us paid much attention to pathogenic CD4+ T cells.
Because it is known that lymphocytes in MS plaques are biased
toward the CD8 lineage, the authors emphasize that understand-
ing how CNS-reactive CD8 T cells escape tolerance induction
and induce CNS autoimmunity is critical to our ability to pro-
pose and test new therapies for MS. It is possible, for example,
that pathogenic CD8+ T cells might play a major role in chronic
inflammation during the course of MS development. Mauro and
Marelli-Berg (2012) report T cell immunity in cardiovascular
metabolic disorders. They proposed that an altered metabolism
in the cardiovascular system initially induced by macrophages
and innate immunity can fuel chronic inflammation and subse-
quent migration of antigen-non-specific activated T cells to the
affected site. Komatsu and Takayanagi (2012) address the syner-
gistic activity of immune cells, particularly activated helper T cells
and mesenchymal cells such as synovial fibroblasts in joints. They
propose that mesenchymal cells, which interact with the acti-
vated T cells, are an important determinant in the development
of chronic inflammation in the joints.
The next two articles show events in the later phase of chronic
inflammation. Ueha et al. (2012) present cellular and molecular
mechanisms of organ fibrosis and Rubin et al. (2012) address the
relationship between IBD and colon cancer, which develops in
the affected sites during chronic inflammation. The authors stress
the formation of myofibroblasts mediated by activated helper
T cells as well as cytokines such as TGFb for the development of
chronic inflammation-mediated fibrosis (Ueha et al., 2012) and
review the genetic basis of IBD, the genetic and cellular alterations
associated with colitis-associated colon cancer, and the emerg-
ing role of the intestinal microbiota and other environmental
factors.
The next three articles address the negative regulation of
chronic inflammation by DHA metabolome, IL-10, and reg-
ulatory T cells (Tregs). Shinohara et al. (2012) present an
overview of functional metabolomics that identified a new bioac-
tive metabolome of docosahexaenoic acid (DHA) including their
recent in vivo and in vitro data. They suggest that the metabolome
of DHAmight have protective and anti-inflammatory actions rel-
evant even in humans. Kubo and Motomura (2012) review the
transcriptional regulation of the anti-inflammatory cytokine, IL-
10, particularly in adaptive immune cells such as activated helper
T cells. Because IL-10 has a strong immune suppressive effect, it
is possible that a reduced IL-10 transcription in the affected tis-
sues can be a triggering factor for chronic inflammation. Fujio
et al. (2012) discuss Tregs, which strongly inhibit chronic inflam-
mation, by paying special attention to autoantibody production
and autoantibody-mediated autoimmune diseases. They con-
clude that several kinds of Tregs have the potential to control
autoimmune inflammation by suppressing both autoantibody
production and the local chronic inflammatory responses that are
induced by autoantibodies.
The next two articles focus on current ambiguities in
immunology. Barnaba et al. (2012) review the various cell pop-
ulations in the immune system. They hypothesize that they main-
tain a state of chronic low-level inflammation during persisting
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infections, and ultimately favor the species survival. Thus, dys-
regulation of low-level inflammation by enhancing harmful
responses and/or reducing negative regulatory responses could
develop into chronic inflammation. Prinz and Knobeloch (2012)
present the good and bad of I-IFN with regards to immune
responses and inflammation induction. I-IFN is associated with
detrimental effects in Aicardi–Goutières syndrome (AGS), but at
the same time is used as a standard therapeutic for the treat-
ment of relapsing–remitting MS. The authors show mainly their
own data for AGS, a severe disabling autoimmune inflammatory
encephalopathy, and experimental autoimmune encephalomyeli-
tis (EAE), a murine model of MS, to describe the roles of
I-IFN during the development of chronic inflammation in
the CNS.
The final report is ours (Murakami and Hirano, 2011).
We have been studying the role of non-immune cells in the
development of helper T cell-mediated autoimmune diseases.
Although the NFκB-triggered positive-feedback-loop for IL-6-
signaling (IL-6-amplifier) was originally discovered in mice to be
a synergistic-activation signal that is activated following IL-17A
and IL-6 stimulation in non-immune cells, results from disease
models such as a rheumatoid arthritis, F759 mice, and EAE have
shown that the IL-6-amplifier in fibroblasts, a type of endothe-
lial cell, is activated by simultaneous stimulation of NFkB and
STAT3 and locally induces chemokines and chronic inflamma-
tion. Indeed, we have proposed a four-step model for MHC class
II-associated autoimmune diseases: (1) T cell activation regardless
of antigen specificity; (2) local events inducing a tissue-specific
accumulation of activated T cells; (3) transient activation of the
IL-6 amplifier; and (4) enhanced sensitivity to cytokines in the
target tissue. The interaction of these events results in chronic
activation of the IL-6 amplifier and subsequent manifestation of
autoimmune diseases. Thus, the IL-6 amplifier, which is chron-
ically activated by these four events, is a critical regulator of
chronic inflammations in tissue-specific MHC class II-associated
autoimmune diseases.
As summarized above, the 13 articles present a range of data
and issues that are under active investigation for understanding
the molecular mechanism(s) of chronic inflammation, which is a
general cause of various human diseases and disorders.
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